USPTO serial 79221183
VACSAF
Reviewed by CopyMark Law Group
Reg. 5651894Status 709
- Filing date
- Status date
- Registration date
- Jan 15, 2019
- Examiner
- MAYER, DAVID COREY
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with VACSAF?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Belfast Co. Antrim BT3 9DT, GB
Belfast Co. Antrim BT3 9DT, GB
Belfast Co. Antrim BT3 9DT, GB
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Helen Hill Minsker
Helen Hill Minsker Banner & Witcoff, Ltd.71 South Wacker DriveSuite 3600Chicago, IL 60606Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals and chemical preparations for use in industry, science and research; Biochemical substances and biochemical preparations for use in industry, science and research, namely, excipients for use in the manufacture of pharmaceutical preparations, cosmetic preparations, nutraceutical preparations, veterinary preparations, dietary supplements, foods and pharmaceutical preparations for topical use; Chemical preparations for pharmaceutical, medical and veterinary research in the nature of reagents and substrates, namely, chemical compounds for use in patterning at nano scale or near nano scale; Silicon for use in industry, science and research; Silicon nanoparticle materials, namely, silicon and silicon-based chemical compounds for use in industry, science and research; Porous silicon nanoparticle materials, namely, silicon and silicon-based chemical compounds for use in industry, science and research; Chemical materials, namely, chemical catalysts for carrying and delivery of chemical, biochemical and biological substances for use in industry and not for medical or veterinary use; Silicon for use in stabilising enzymes of chemical, biochemical and biological substances for scientific research purposes; Nanoparticle materials, namely, silicon-based chemical compounds for use in stabilising enzymes of chemical, biochemical and biological substances for scientific research purposes; Silicon nanoparticle materials being silicon-based chemical compounds for use in stabilising enzymes of chemical, biochemical and biological substances for scientific research purposes; Porous silicon nanoparticle materials being silicon-based chemical compounds for stabilising enzymes of chemical, biochemical and biological substances for use in industry and for scientific research purposes; Chemicals and chemical preparations, namely, reagents and catalysts for pharmaceutical research purposes; Chemicals and chemical preparations, namely, reagents and catalysts for scientific research in the field of medicine, veterinary and pharmaceutics; Excipient for use in the manufacture of pharmaceutical products, including for the manufacture of vaccines and veterinary preparations | SECTION 71 - CANCELLED | — |
| 005 | Antiviral pharmaceutical preparations, anti-infective pharmaceutical preparations, anti-inflammatory pharmaceutical preparations, antiseptic pharmaceutical preparations, antibacterial pharmaceutical preparations, antibiotic pharmaceutical preparations, antifungal pharmaceutical preparations, and anti-fibrotic pharmaceutical preparations; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the treatment and prevention of cardiovascular diseases and disorders, musculoskeletal diseases and disorders, inflammatory diseases and disorders, respiratory diseases and disorders, pulmonary diseases and disorders, immune system related diseases and disorders, hematological diseases and disorders, oncological diseases and disorders, urological diseases and disorders, gastro-intestinal diseases, eye diseases and conditions, heart rhythm disorders, kidney diseases, nephropathic diseases, hematological disorders, diabetes, hypertension, skin disorders, damaged skin and tissue, wrinkles, wounds and allergies, insect bites, dermatological diseases and disorders, HIV, cancer and tumors, bone diseases, arthritis, cardiopulmonary diseases and disorders, infectious diseases, blood disorders, pain, sepsis, alopecia, obesity, cognitive disorders and diseases, neurological disorders, hormonal disorders, disorders of the autoimmune system, metabolic system diseases and disorders, endocrine system diseases and disorders, genitourinary system diseases and disorders; Preparations in the nature of animal feed supplements containing trace elements; Preparations in the nature of human vaccine preparations containing trace elements; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals, nutraceutical and veterinary products; Drug delivery agents consisting of nanoparticle compounds that facilitate delivery of a wide range of pharmaceutical, nutraceutical and veterinary products; Drug delivery agents consisting of silicon compounds that facilitate delivery of a wide range of pharmaceutical, nutraceutical and veterinary products; Drug delivery agents consisting of porous silicon compounds that facilitate delivery of a wide range of pharmaceutical, nutraceutical and veterinary products; drug delivery agents consisting of compounds for facilitating the delivery of chemical, biochemical, biological, and pharmaceutical vaccines; Drug delivery agents consisting of compounds containing silicon-based nanoparticles for facilitating the delivery of chemical, biochemical, biological, and pharmaceutical vaccines; Drug delivery agents consisting of compounds containing silicon-based porous nanoparticles for facilitating the delivery of chemical, biochemical, biological, and pharmaceutical vaccines; Drug delivery agents consisting of compounds for facilitating the delivery of chemical, biochemical, biological, and pharmaceutical antibiotics; drug delivery agents consisting of compounds containing silicon-based nanoparticles for facilitating the delivery of chemical, biochemical, biological, and pharmaceutical antibiotics; drug delivery agents consisting of compounds containing silicon-based porous nanoparticles for facilitating the delivery of chemical, biochemical, biological, and pharmaceutical antibiotics; Chemical, biochemical, biological and pharmaceutical substances for medicinal use being pharmaceutical preparation stabilizers | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 1, 2026 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Aug 1, 2025 | C71T | CANCELLED SECTION 71 | — |
| Jan 15, 2024 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| May 17, 2019 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| May 1, 2019 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Apr 30, 2019 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Apr 15, 2019 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jan 15, 2019 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 14, 2018 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 30, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 30, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 26, 2018 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Oct 10, 2018 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Oct 10, 2018 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Oct 10, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 18, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 18, 2018 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 18, 2018 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 18, 2018 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 18, 2018 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 31, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 31, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 30, 2018 | ALIE | ASSIGNED TO LIE | — |
| Aug 15, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 9, 2018 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 16, 2018 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 16, 2018 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 13, 2018 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 12, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 6, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 29, 2017 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 25, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 16, 2017 | SDRC | SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB | — |